Amino Acid, Peptide, or Protein – Page 69

Pharmaceutical Giants Sanofi, Pfizer, and AstraZeneca Pump $1.87 Billion into French Operations

12 months ago talkbio0Tagged AstraZeneca, development aspects, Drug Industry, France, Investments, Manufacture, Pfizer, production, research, sanofi, Surgical aspects, Vaccines

Sanofi, Pfizer, AstraZeneca, France, investment, pharmaceutical industry, operations, vaccine production, research and development, manufacturing.

Evaluating the Impact of a Dose-Optimization App on Zestril Efficacy for Hypertension Management

12 months ago talkbio0Tagged blood pressure management, closed-loop testing, Dose-Optimization, Effectiveness, Hypertensive disease, Zestril

Zestril, hypertension, dose-optimization, app, closed-loop testing, efficacy, blood pressure management.

AstraZeneca’s COVID-19 Antibody Treatment Shows Promising Results in Immunocompromised Individuals

12 months ago talkbio0Tagged Antibodies, AstraZeneca, Clinical Trials, COVID19 (disease), Enhance (action), Immune response, Immunocompromised Host, individuals, Monoclonal Antibodies, Neutralization (Chemistry), Protection, Virus

AstraZeneca, COVID-19, antibody treatment, immunocompromised individuals, enhanced protection, clinical trials, monoclonal antibodies, virus neutralization, immune response.

AstraZeneca’s Next-Generation Covid Therapy Shines in Phase 3 Trials

12 months ago talkbio0Tagged Antibodies, AstraZeneca, COVID19 (disease), Effectiveness, Evusheld, next-generation therapy, Phase 3 trials, Safety, successor

AstraZeneca, Covid-19, Evusheld, Phase 3 trials, next-generation therapy, successor, antibody treatment, prevention, efficacy, safety.

Lilly’s Weekly Insulin Therapy Excels in Two Major Clinical Trials, Narrowing Gap with Novo Nordisk

12 months ago talkbio0Tagged Administration occupational activities, Clinical Trials, Diabetes, Drug Industry, Eli Lilly, Insulin, insulin therapy, Nordisk, Primary Endpoint, trials, Weekly

Lilly, Novo Nordisk, weekly insulin, primary endpoint, pivotal trials, diabetes management, insulin therapy, clinical trials, diabetes treatment, pharmaceutical industry.

Johnson & Johnson Expands into IL-13 and TSLP Market with Strategic Acquisition

12 months ago talkbio0Tagged Acquisition (action), Biological Factors, competition, Drug Industry, expansion, I&I, Inflammatory disorder, Interleukin-13, Johnson and Johnson, Market, strategic, TSLP gene

Johnson & Johnson, I&I acquisition, IL-13, TSLP, competitive market, strategic expansion, pharmaceutical industry, biologics, inflammatory diseases.

FDA Rejects Hepatitis B Vaccine Update Due to Inadequate Documentation and Data

12 months ago talkbio0Tagged Destructive procedure (surgical), Documents, hepatitis B surface antigen vaccine, Inadequate (qualifier), Rejection (Psychology), United States Food and Drug Administration, Vaccines

FDA, hepatitis B vaccine, vaccine update, document destruction, insufficient data, rejection

Eisai and Biogen Overcome Filing Hitch, Initiate FDA Submission for Subcutaneous Leqembi

12 months ago talkbio0Tagged Alzheimer 's disease, Amyloid beta-Peptides, Biogen, Blackfoot language, Clinical Trials, Eisai, Leqembi, Monoclonal Antibodies, rolling, subcutaneous, Submission, United States Food and Drug Administration

Eisai, Biogen, FDA submission, Leqembi, subcutaneous, Alzheimer’s disease, rolling submission, BLA, clinical trials, monoclonal antibody, amyloid beta, neurodegenerative disorder